Literature DB >> 19667399

Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal.

Michael Heuser1, Laura M Sly, Bob Argiropoulos, Florian Kuchenbauer, Courteney Lai, Andrew Weng, Malina Leung, Grace Lin, Christy Brookes, Stephen Fung, Peter J Valk, Ruud Delwel, Bob Löwenberg, Gerald Krystal, R Keith Humphries.   

Abstract

Although the cancer stem cell (CSC) concept implies that CSCs are rare, recent reports suggest that CSCs may be frequent in some cancers. We hypothesized that the proportion of leukemia stem cells would vary as a function of the number of dysregulated pathways. Constitutive expression of MN1 served as a 1-oncogene model, and coexpression of MN1 and a HOX gene served as a 2-oncogene model. Leukemia-initiating cell (LIC) number and in vitro expansion potential of LICs were functionally assessed by limiting dilution analyses. LIC expansion potential was 132-fold increased in the 2- compared with the 1-oncogene model, although phenotypically, both leukemias were similar. The 2-oncogene model was characterized by granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity and activated STAT/ERK signaling. GM-CSF hypersensitivity of the 2-oncogene model (MN1/HOXA9) was lost in Stat5b(-/-) cells, and the LIC expansion potential was reduced by 86- and 28-fold in Stat5b(-/-) and Stat1(-/-) cells, respectively. Interestingly, in 201 acute myeloid leukemia (AML) patients, coexpression of MN1 and HOXA9 was restricted to patients with the poorest prognosis and was associated with highly active STAT signaling. Our data demonstrate the functional heterogeneity of LICs and show that STAT signaling is critical for leukemia stem cell self-renewal in MN1- and HOXA9-expressing leukemias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667399     DOI: 10.1182/blood-2009-06-227603

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.

Authors:  Yusuke Takeda; Chiaki Nakaseko; Hiroaki Tanaka; Masahiro Takeuchi; Makiko Yui; Atsunori Saraya; Satoru Miyagi; Changshan Wang; Satomi Tanaka; Chikako Ohwada; Emiko Sakaida; Naoto Yamaguchi; Koutaro Yokote; Lothar Hennighausen; Atsushi Iwama
Journal:  Br J Haematol       Date:  2011-04-15       Impact factor: 6.998

3.  STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

Authors:  Winnie F Tam; Patricia S Hähnel; Andrea Schüler; Benjamin H Lee; Rachel Okabe; Nan Zhu; Saskia V Pante; Glen Raffel; Thomas Mercher; Gerlinde Wernig; Ernesto Bockamp; Daniel Sasca; Andreas Kreft; Gertraud W Robinson; Lothar Hennighausen; D Gary Gilliland; Thomas Kindler
Journal:  Cancer Res       Date:  2012-11-13       Impact factor: 12.701

4.  Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.

Authors:  Christine Vogtenhuber; Christoph Bucher; Steven L Highfill; Lisa K Koch; Emily Goren; Angela Panoskaltsis-Mortari; Patricia A Taylor; Michael A Farrar; Bruce R Blazar
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

5.  MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.

Authors:  Simone S Riedel; Jessica N Haladyna; Matthew Bezzant; Brett Stevens; Daniel A Pollyea; Amit U Sinha; Scott A Armstrong; Qi Wei; Roy M Pollock; Scott R Daigle; Craig T Jordan; Patricia Ernst; Tobias Neff; Kathrin M Bernt
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

6.  A structured population model of clonal selection in acute leukemias with multiple maturation stages.

Authors:  Tommaso Lorenzi; Anna Marciniak-Czochra; Thomas Stiehl
Journal:  J Math Biol       Date:  2019-07-26       Impact factor: 2.259

7.  Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.

Authors:  Bin Zhang; Ling Li; Yinwei Ho; Min Li; Guido Marcucci; Wei Tong; Ravi Bhatia
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

8.  Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13.

Authors:  Suzan Imren; Michael Heuser; Maura Gasparetto; Philip A Beer; Gudmundur L Norddahl; Ping Xiang; Ling Chen; Tobias Berg; Garrett W Rhyasen; Patricia Rosten; Gyeongsin Park; Yeonsook Moon; Andrew P Weng; Connie J Eaves; R Keith Humphries
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

9.  Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.

Authors:  Suhu Liu; Sarah R Walker; Erik A Nelson; Robert Cerulli; Michael Xiang; Patricia A Toniolo; Jun Qi; Richard M Stone; Martha Wadleigh; James E Bradner; David A Frank
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

Review 10.  Understanding the cancer stem cell.

Authors:  S Bomken; K Fiser; O Heidenreich; J Vormoor
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.